The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells
Figure 6
Combined effect of U0126 and troglitazone on PC-3 cell proliferation. (a) PC-3 cells were first plated in 6-well plates at a density of 10,000 cells/well. The cells were then treated with DMSO vehicle or troglitazone (10–40 μM) in the presence or absence of 10 μM U0126. [3H]-thymidine incorporation assays were then used to measure proliferation of treated cells. (b) PC-3 cells were plated in 6-well plates at a density of 10,000 cells/well and treated for six days with DMSO vehicle or troglitazone in the presence or absence of 10 μM U0126. Following treatment, the cells were detached using trypsin-EDTA and counted using a Coulter Counter. For both panels, each bar represents the mean ± SD for three wells. * compared to DMSO control. ** compared to U0126 alone and 10 μM troglitazone alone.
